雷珠单抗玻璃体腔注射治疗新生血管性青光眼患者的临床疗效

Clinical observation of intravitreal injection of ranibizumab in the treatment of neovascular glaucoma

下载PDF

导出

摘要目的观察雷珠单抗玻璃体腔注射治疗新生血管性青光眼患者的临床疗效。方法选取2018年2月至2020年6月本院接收的74例新生血管性青光眼患者作为研究对象,依据入院前后顺序分为对照组与观察组,各37例。对照组予以手术治疗,观察组在对照组基础上运用雷珠单抗玻璃体腔注射治疗,比较两组治疗前后眼压水平、视力提高率及并发症发生率。结果治疗前,两组眼压水平比较差异无统计学意义;治疗后,观察组眼压明显低于对照组(P<0.05)。观察组视力提高率为94.59%,高于对照组的70.27%,差异有统计学意义(P<0.05)。观察组并发症发生率为5.41%,低于对照组的29.73%,差异有统计学意义(P<0.05)。结论采用雷珠单抗玻璃体腔注射治疗新生血管性青光眼疗效显著,可改善患者眼压,提高视力,且安全性高,值得临床推广应用。 Objective To observe the clinical efficacy of intravitreal injection of ranibizumab in the treatment of neovascular glaucoma.Methods 74 neovascular glaucoma patients accepted by our hospital from February 2018 to June 2020 were selected as the research subjects,and they were divided into control group and observation group according to the order before and after admission,with 37 cases in each group.The control group received surgical treatment,and the observation group received intravitreal injection of ranibizumabon the basis of the control group,the intraocular pressure level before and after treatment,visual acuity improvement rate and complication rate between the two groups were compared.Results Before treatment,there was no difference in the intraocular pressure between the two groups;after treatment,the intraocular pressure of the observation group was significantly lower than control group(P<0.05);the visual acuity improvement rate in the observation group was 94.59%,which was higher than 70.27%in the control group,thedifference was statistically significant(P<0.05);the incidence of complications in the observation group was 5.41%,lower than 29.73%in the control group,and the difference was statistically significant(P<0.05).Conclusion Intravitreal injection of ranibizumab in the treatment of neovascular glaucoma has significant effect,can improve the intraocular pressure of patients,improve visual acuity,and high safety,worthy of clinical application.

作者张凤 ZHANG Feng(Department of Ophthalmology,Zaozhuang Hospital,Zaozhuang Mining Group,Heze,Shandong,277100,China)

机构地区枣庄矿业集团枣庄医院眼科

出处《当代医学》 2022年第29期71-73,共3页 Contemporary Medicine

关键词雷珠单抗玻璃体腔注射新生血管性青光眼眼压视力提高率并发症 Ranibizumab Intravitreal injection Neovascular glaucoma Intraocular pressure Visual acuity improvement rate Complications

分类号 R47 [医药卫生—护理学]